PubMed · 6006077
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
E R Long. DDS and malaria.. https://pubmed.ncbi.nlm.nih.gov/6006077/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Dapsone is a drug of choice in the treatment of leprosy. In addition it is very useful in the treatment of many other dermatological conditions. The "dapsone-induced hypersensitivity" is not unknown. However, to the best of our knowledge, pulmonary eosinophilia induced by dapsone without any cutaneous allergic manifestation has not been reported in leprosy patients. Pulmonary eosinophilia (Loeffler's syndrome) induced by dapsone without cutaneous manifestation has been reported in a non leprosy patient by Janier et al. We report a case of pulmonary eosinophilia associated with dapsone therapy in a patient with lepromatous leprosy without allergic cutaneous manifestations and our experience in the management of this patient.
Morphological findings in serial nasal mucosal biopsies from three cases of rhinosporidiosis on dapsone therapy were compared with biopsies from 33 patients taken before dapsone or surgical treatment was initiated. All biopsies were examined by light microscopy and five by electron microscopy. Counts of histologically intact and degenerated organisms showed a decreasing proportion of intact forms with treatment.
Prof. Morizo Ishidate synthesized "Promin" for the treatment of leprosy/Hansen's disease which had been considered "incurable" until the discovery of antileprosy effect of that drug by Dr. Faget of U.S.A. in 1941. Prof. Ishidate was the first to synthesize the drug in Japan in 1946 based on a brief news item on a Swiss journal smuggled in during the War. For this achievement, he is known as "father of chemotherapy for leprosy in Japan." Prof. Ishidate also contributed to the global fight against leprosy as the Chairman of the Board of Directors of Sasakawa Memorial Health Foundation, which he helped to establish in May 1974, with a full financial backing of Mr. Ryoichi Sasakawa, President of Japan Shipbuilding Industry Foundation. Prof. Ishidate, with his scientific knowledge as well as christianity based humanitarian concern, advised Mr. Sasakawa how to spend JSIF money wisely for eliminating leprosy and nearly US$200 million was channeled through WHO and SMHF. The successful outcome of global multidrug therapy (MDT) programme in the '80s resulted in the adoptation of resolution by the World Health Assembly, "Elimination of Leprosy, as a public health problem" by the Year 2000. The synthesis of "Promin" in Japan and promoting the global implementation of MDT, both achievement can be attributed to Prof. Ishidate.